- Nonketotic hyperglycinemia (NKH), also known as glycine encephalopathy, is an inherited metabolic disorder characterized by abnormally high concentrations of glycine in the body, particularly in the central nervous system. The condition is primarily associated with impaired activity of the glycine cleavage system (GCS), the mitochondrial pathway responsible for the degradation of glycine. Because the glycine cleavage system connects glycine degradation with one-carbon and folate metabolism, defects in this pathway can affect several aspects of cellular metabolism. The neurological manifestations of nonketotic hyperglycinemia are also related to the important role of glycine as a neurotransmitter and its ability to modulate neuronal signaling.
- Under normal conditions, glycine is continuously produced, utilized, transported, and degraded as part of glycine metabolism. It can be incorporated into proteins, converted to or from serine, used in purine synthesis, contribute to glutathione synthesis, participate in collagen production, and function as a neurotransmitter. Excess glycine can be degraded primarily through the mitochondrial glycine cleavage system. When this pathway is impaired, glycine cannot be metabolized efficiently and can accumulate in tissues and body fluids.
- The glycine cleavage system is a multicomponent mitochondrial pathway consisting of four functional components known as the P protein, H protein, T protein, and L protein. The P protein is glycine dehydrogenase and is encoded by the GLDC gene. The H protein is encoded by GCSH and contains a lipoyl group that carries reaction intermediates between the different components. The T protein, encoded by AMT, is aminomethyltransferase and transfers the aminomethyl group derived from glycine to tetrahydrofolate. The L protein is encoded by DLD and participates in the regeneration of the oxidized H protein. Defects affecting several of these components can impair glycine degradation.
- The glycine cleavage reaction normally converts glycine into carbon dioxide, ammonia, and a folate-bound one-carbon unit. The one-carbon component is transferred to tetrahydrofolate, producing 5,10-methylene-THF, which can enter the broader one-carbon metabolism network. This makes the glycine cleavage system important not only for controlling glycine concentrations but also for supplying one-carbon units for cellular metabolism. Impairment of the pathway therefore represents a disruption of both glycine degradation and a component of folate-dependent metabolism.
- The genetic basis of nonketotic hyperglycinemia is heterogeneous. Pathogenic variants in GLDC are among the most common causes and affect the P protein of the glycine cleavage system. Variants in AMT can affect the T protein, while variants in GCSH can affect the H protein. In some cases, defects involving other components or associated metabolic mechanisms can produce related biochemical abnormalities. The exact genetic variant can influence the residual activity of the affected protein and consequently the severity and clinical course of the disorder.
- The term “nonketotic” refers to the biochemical pattern in which elevated glycine occurs without the characteristic increase in ketone bodies associated with certain other metabolic disorders. This distinction is useful because several inherited metabolic diseases can produce abnormal amino acid concentrations, but they differ in their effects on organic acids, ketone production, and other metabolic pathways. Diagnosis therefore requires evaluation of the overall biochemical profile rather than relying on glycine concentration alone.
- A major biochemical feature of nonketotic hyperglycinemia is an increased plasma glycine concentration together with an increased glycine concentration in the cerebrospinal fluid (CSF). The relationship between glycine concentrations in plasma and CSF can provide important diagnostic information. Because glycine is an important neurotransmitter and neuromodulator, excessive glycine in the central nervous system can contribute to abnormal neuronal signaling. Laboratory evaluation commonly combines biochemical measurements with molecular genetic testing to establish the diagnosis.
- The neurological effects of nonketotic hyperglycinemia are closely connected to the functions of glycine in the nervous system. Glycine can act as an inhibitory neurotransmitter through glycine receptors, particularly in the spinal cord and brainstem. At the same time, glycine can act as a co-agonist at NMDA receptors, which are involved in excitatory neurotransmission, synaptic plasticity, learning, and memory. Abnormal glycine concentrations can therefore influence neuronal signaling through more than one receptor system.
- The clinical presentation of nonketotic hyperglycinemia can vary considerably. Severe forms can present during the neonatal period, while other forms may become apparent later in infancy, childhood, or adulthood. Neurological manifestations can include hypotonia, abnormal movements, seizures, developmental impairment, and disturbances of consciousness. The specific presentation depends on factors such as the underlying genetic variant, residual enzyme activity, age at presentation, and the overall metabolic effects of the disorder.
- Severe neonatal presentations can involve profound neurological abnormalities soon after birth. Infants may develop marked hypotonia, feeding difficulties, lethargy, abnormal respiratory patterns, seizures, and impaired responsiveness. Some individuals with severe disease can experience significant neurological impairment. Later-onset forms may have a different clinical pattern and can include developmental, behavioral, movement, or seizure-related manifestations. The variability in presentation reflects the heterogeneous nature of defects affecting glycine degradation.
- The effects of nonketotic hyperglycinemia are not limited to glycine concentration itself. Impaired glycine cleavage can alter the flow of carbon through one-carbon metabolism because the glycine cleavage system normally transfers an aminomethyl group to tetrahydrofolate. This produces 5,10-methylene-THF, an important intermediate in folate metabolism. The degree to which this affects downstream one-carbon reactions may depend on the severity and specific location of the metabolic defect.
- The relationship between glycine and serine is also relevant. Serine hydroxymethyltransferase (SHMT) catalyzes the reversible conversion of serine and glycine while transferring one-carbon units through tetrahydrofolate. Consequently, impaired glycine degradation can alter the balance among glycine, serine, and folate-bound one-carbon metabolites. The interaction between these pathways illustrates why metabolic disorders involving a single enzyme system can produce effects across a broader metabolic network.
- Glycine accumulation also has implications for amino acid homeostasis. Cellular amino acid concentrations are maintained through a balance between dietary intake, endogenous synthesis, protein degradation, transport, interconversion, and catabolism. When one major degradation pathway is impaired, the corresponding amino acid can accumulate and influence related metabolic reactions. In nonketotic hyperglycinemia, the glycine pool is affected primarily because mitochondrial glycine cleavage is reduced.
- The biochemical diagnosis of nonketotic hyperglycinemia generally involves measurement of glycine and assessment of the relationship between glycine concentrations in plasma and cerebrospinal fluid. Additional metabolic testing can help exclude other disorders that produce abnormal glycine levels. Molecular genetic testing can then identify pathogenic variants in genes associated with the glycine cleavage system. The combination of biochemical and genetic information provides a more complete understanding of the underlying defect.
- Genetic sequencing is particularly important because many different variants can affect the same gene. Variants can include missense changes, nonsense variants, splice-site variants, small insertions or deletions, and other types of genomic alterations. Their effects may involve protein folding, enzyme stability, catalytic activity, mitochondrial targeting, or interactions with other components of the glycine cleavage system. Bioinformatics and computational variant interpretation can help evaluate the likely consequences of sequence changes, although functional evidence may be necessary for uncertain variants.
- The GLDC gene is particularly important in the molecular diagnosis of nonketotic hyperglycinemia. GLDC encodes glycine dehydrogenase, the P protein that performs the initial decarboxylation step of the glycine cleavage reaction. A pathogenic GLDC variant can reduce or eliminate P-protein activity, limiting the ability of mitochondria to initiate glycine degradation. The resulting accumulation of glycine can contribute to the characteristic biochemical and neurological features of the disorder.
- AMT is another important gene associated with nonketotic hyperglycinemia. It encodes the T protein, aminomethyltransferase, which transfers the aminomethyl group from the H protein to tetrahydrofolate. Impaired T-protein activity interrupts an essential step in glycine cleavage even if the initial interaction between glycine and the P protein can occur. GCSH encodes the H protein, whose lipoyl group serves as a carrier during the reaction. Disruption of this component can therefore also interfere with the coordinated transfer of reaction intermediates.
- DLD encodes dihydrolipoamide dehydrogenase, the L protein of the glycine cleavage system. Unlike GLDC, AMT, and GCSH, DLD is involved in several mitochondrial dehydrogenase complexes. Consequently, defects in DLD can affect multiple metabolic pathways rather than the glycine cleavage system alone. This broader role is important when interpreting biochemical and clinical findings in individuals with DLD-related metabolic disease.
- The diagnosis and study of nonketotic hyperglycinemia also demonstrate the importance of metabolic pathway analysis. Measuring a single metabolite provides limited information about the underlying mechanism. By examining glycine together with other amino acids, organic acids, folate-related metabolites, and relevant biochemical markers, researchers and clinicians can obtain a more comprehensive picture of metabolic function. This approach is particularly useful when different inherited disorders produce overlapping biochemical abnormalities.
- Metabolomics provides additional tools for studying nonketotic hyperglycinemia. Global measurements of metabolites can help identify changes in glycine, serine, folate-related compounds, amino acid pathways, and other metabolic networks. Stable-isotope tracing can potentially be used in research settings to investigate how carbon flows through glycine and one-carbon pathways. These approaches can help clarify how genetic defects alter metabolic flux and how cells compensate for impaired glycine degradation.
- Structural biology also contributes to understanding the disease. Structures of the P, H, T, and L components can provide information about catalytic sites, cofactor-binding regions, protein interactions, and the structural effects of disease-associated variants. Techniques such as X-ray crystallography, NMR spectroscopy, and other structural methods can help researchers understand how specific amino acid substitutions or other genetic changes alter protein function.
- The relationship between nonketotic hyperglycinemia and neurotransmission makes this disorder particularly important for understanding the connection between metabolism and nervous-system function. Glycine is both a metabolic substrate and a signaling molecule. It participates in mitochondrial degradation pathways while also acting in neuronal communication. When glycine concentrations become abnormally elevated, the distinction between metabolic and signaling functions becomes especially important because changes in metabolite concentration can influence receptor-mediated neuronal processes.
- Glycine receptors are ligand-gated chloride channels that mediate inhibitory neurotransmission in many regions of the central nervous system. Glycine also acts as a co-agonist at NMDA receptors, where it contributes to receptor activation together with glutamate. These two roles mean that altered glycine availability can influence different aspects of neuronal signaling. The neurological manifestations of nonketotic hyperglycinemia therefore reflect the intersection of metabolic dysfunction and neurotransmitter biology.
- Management of nonketotic hyperglycinemia is complex because the underlying genetic defect affects a fundamental metabolic pathway. Clinical care generally focuses on controlling neurological manifestations and reducing the consequences of excessive glycine signaling. Treatment approaches can vary according to disease severity, age, clinical presentation, and the underlying molecular defect. Because this is a specialized inherited metabolic disorder, management typically involves multidisciplinary metabolic and neurological expertise.
- Research into nonketotic hyperglycinemia also contributes to the broader study of inborn errors of metabolism. These disorders demonstrate how changes in a single enzyme or metabolic pathway can influence multiple biological systems. The glycine cleavage system provides an especially clear example because it connects amino acid degradation, folate-dependent one-carbon metabolism, mitochondrial function, and neurotransmission. Studying the disorder therefore provides insights into both metabolic biochemistry and neurological physiology.
- The glycine cleavage system is also important outside human disease. In plants, glycine cleavage participates in photorespiration, while microorganisms use related pathways for glycine and one-carbon metabolism. These systems illustrate the evolutionary conservation of glycine-processing mechanisms and provide experimental models for understanding enzyme structure, reaction mechanisms, and metabolic regulation.
- From a broader metabolic perspective, nonketotic hyperglycinemia demonstrates the importance of maintaining glycine homeostasis. Glycine must be available in sufficient amounts for protein synthesis, collagen production, nucleotide metabolism, glutathione synthesis, and neurotransmission, but excessive accumulation can disrupt physiological processes. The glycine cleavage system is therefore an important component of the mechanisms that maintain appropriate glycine concentrations.
- Understanding the relationship between glycine and nonketotic hyperglycinemia requires integrating several levels of biology, including glycine metabolism, mitochondrial biochemistry, enzyme mechanisms, genetics, neurotransmission, folate metabolism, one-carbon metabolism, and clinical biochemistry. Genetic variants affecting GLDC, AMT, or GCSH can impair the glycine cleavage system and lead to abnormal glycine accumulation. Studying these pathways provides an example of how molecular changes can propagate through metabolic networks and ultimately influence cellular and neurological function.
- Nonketotic hyperglycinemia therefore represents an important example of the connection between amino acid metabolism and human disease. The disorder arises primarily from impaired glycine degradation through the mitochondrial glycine cleavage system, leading to elevated glycine concentrations and neurological effects. At the same time, the pathway is connected to folate-dependent one-carbon metabolism, serine metabolism, mitochondrial redox processes, and amino acid homeostasis. Continued research using genetics, biochemistry, metabolomics, bioinformatics, and structural biology is helping to clarify the molecular mechanisms underlying this complex metabolic disorder.
